Novel Tubeimoside I liposomal drug delivery system in combination with gemcitabine for the treatment of pancreatic cancer.

IF 3.9 Nanomedicine (London, England) Pub Date : 2024-01-01 Epub Date: 2024-09-03 DOI:10.1080/17435889.2024.2382076

Shuhui Li, Yuansheng Liu, Xiaojun Sui, Yuzhen Zhuo, He Siqi, Zhang Sijia, Zhang Hui, Li Dihua, Zhang Dapeng, Yang Lei

{"title":"Novel Tubeimoside I liposomal drug delivery system in combination with gemcitabine for the treatment of pancreatic cancer.","authors":"Shuhui Li, Yuansheng Liu, Xiaojun Sui, Yuzhen Zhuo, He Siqi, Zhang Sijia, Zhang Hui, Li Dihua, Zhang Dapeng, Yang Lei","doi":"10.1080/17435889.2024.2382076","DOIUrl":null,"url":null,"abstract":"Aim: To evaluate the anti-pancreatic cancer effect of novel Tubeimoside I multifunctional liposomes combined with gemcitabine.Methods: Liposomes were prepared through the thin film hydration method, with evaluations conducted on parameters including encapsulation efficiency (EE%), particle size, polydispersity index (PDI), zeta potential (ZP), storage stability, and release over a 7-day period. The cellular uptake rate, therapeutic efficacy in vitro and in vivo and the role of immune microenvironment modulation were evaluated.Results: The novel Tubeimoside I multifunctional liposomal exhibited good stability, significant anti-cancer activity, and immune microenvironment remodeling effects. Furthermore, it showed a safety profile.Conclusion: This study underscores the potential of Novel Tubeimoside I multifunctional liposomal as a promising treatment option for pancreatic cancer.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"1977-1993"},"PeriodicalIF":3.9000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11485868/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanomedicine (London, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17435889.2024.2382076","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/3 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To evaluate the anti-pancreatic cancer effect of novel Tubeimoside I multifunctional liposomes combined with gemcitabine.Methods: Liposomes were prepared through the thin film hydration method, with evaluations conducted on parameters including encapsulation efficiency (EE%), particle size, polydispersity index (PDI), zeta potential (ZP), storage stability, and release over a 7-day period. The cellular uptake rate, therapeutic efficacy in vitro and in vivo and the role of immune microenvironment modulation were evaluated.Results: The novel Tubeimoside I multifunctional liposomal exhibited good stability, significant anti-cancer activity, and immune microenvironment remodeling effects. Furthermore, it showed a safety profile.Conclusion: This study underscores the potential of Novel Tubeimoside I multifunctional liposomal as a promising treatment option for pancreatic cancer.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

新型 Tubeimoside I 脂质体给药系统与吉西他滨联合治疗胰腺癌。

目的：评估新型 Tubeimoside I 多功能脂质体联合吉西他滨的抗胰腺癌效果：方法：采用薄膜水合法制备脂质体，并对其封装效率（EE%）、粒度、多分散指数（PDI）、ZP、储存稳定性和 7 天释放等参数进行评估。对细胞摄取率、体外和体内疗效以及免疫微环境调节作用进行了评估：结果：新型 Tubeimoside I 多功能脂质体具有良好的稳定性、显著的抗癌活性和免疫微环境重塑作用。此外，它还显示出良好的安全性：本研究强调了新型 Tubeimoside I 多功能脂质体作为胰腺癌治疗选择的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

文献相关原料

公司名称

产品信息

阿拉丁

Coumarin-6

来源期刊